SCHEMBL17397203

SCHEMBL17397203

CC(=O)c1cc2ccccn2c(=O)c1-c1ccccc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.44
MEN1 O00255 3/20 0.44
ALDH1A1 P00352 3/20 0.44
KMT2A Q03164 3/20 0.44
TDP1 Q9NUW8 2/20 0.44
RECQL P46063 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.43
TRPV1 Q8NER1 2/20 0.43
RAB9A P51151 2/20 0.42
KDM4E B2RXH2 2/20 0.42
BRD4 O60885 1/20 0.41
THRB P10828 1/20 0.40
PIK3CD O00329 1/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
NPC1 O15118 1/20 0.40
BAZ2B Q9UIF8 2/20 0.39
BAZ2A Q9UIF9 2/20 0.39
TSHR P16473 1/20 0.38
PPARG P37231 2/20 0.38
NCOR2 Q9Y618 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17713843 0.85 MAPT (0.56) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL17397108 0.81 PIK3CD (0.44) MAPTALDH1A1TDP1KDM4EBRD4
SCHEMBL17331989 0.80 TRPV1 (0.57) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL17397208 0.79 MAPT (0.41) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL17397188 0.77 PIK3CD (0.41) MAPTMEN1ALDH1A1KMT2ARECQL
SCHEMBL17397106 0.76 MAPT (0.45) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL19836871 0.75 PIK3CD (0.52) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL19836893 0.73 PIK3CD (0.47) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL17713840 0.73 MAPT (0.42) MAPTMEN1ALDH1A1KMT2ATDP1
SCHEMBL17397126 0.72 PIK3CD (0.52) MAPTMEN1ALDH1A1KMT2ATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-9944639-B2 Quinolizinone derivatives as PI3K inhibitors LUPIN LIMITED (IN) 2018-04-17 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2017-05-18 US disclosed
EP-3164400-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS Lupin Limited (IN) 2017-05-10 EP disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed
WO-2016001855-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS LUPIN LIMITED (IN) 2016-01-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170137421-A1 QUINOLIZINONE DERIVATIVES AS PI3K INHIBITORS PIK3R5, PIK3R1, PIK3R4 MAPT 1030/4885MEN1 1731/4885ALDH1A1 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.